We describe an improved method for the determination of islet amyloid polypeptide (lAPP) levels in plasma. Plasma is first extracted with acid-acetone, followed by a specific and sensitive radioimmunoassay (RIA) for lAPP using rabbitanti-human-lAPP serum. Recovery of synthetic lAPP from plasma was 82 ± 6% (n = 16). Standard samples, prepared in 'hormone-free' serum, were also extracted with acid-acetone. Displacement curves of serially diluted acid-acetone extracted plasma samples were parallel to the standard curve. The lower detection limit of the
RIA was 2· 3 ±O' 1 fmollsample (n =5). Intra-assay variations for lAPP concentrations of 4, 17 and 32 pM were 16' 3% (n = 10), 9· 2070 (n = 10) and 6· 2070 (n = 10); interassay variations were 35'9070 (n = 14), 19 '9070 (n = 15) and 15'4070 (n = 15), respectively.
Non-stimulated lAPP levels ranged from 2· 4 to 12 pM (mean 6 ± 4 pM, n = 10)
in healthy control subjects. lAPP was not detectable in type 1 (insulin-dependent) diabetic patients before and after glucagon administration. In type 2 (non-insulindependent) diabetic patients basal levels ranged from 2'2 to 14' 5 pM and glucagonstimulated levels ranged from 2·2 to 38·9 pM. The increase in lAPP varied from Ot024·4pM. The anti-human-IAPP serum had full cross-reactivity with rat lAPP (= mouse lAPP). Transgenic mice overexpressing the human lAPP gene showed elevated plasma lAPP levels as compared to (non-transgenic) control mice.
It is concluded that the method presented for the determination of lAPP in plasma is reliable and easy to perform, yielding reproducible results. The ability to measure plasma lAPP levels will help to elucidate the physiological function of lAPP as well as its pathophysiological role in type 2 diabetes mellitus.
Additional key phrases: islet amyloid polypeptide; amylin; radioimmunoassay; diabetes mellitus; glucagon stimulation
Islet amyloid polypeptide (lAPP) or amy lin was discovered as the major constituent of pancreatic insulinoma amyloid'P and of pancreatic islet amyloid deposits present in patients with type 2 (non-insulin-dependent) diabetes mellitus (NIDDM). 3 lAPP is a 37 amino acid polypeptide which has 46070 amino acid sequence homology with calcitonin gene-related peptide-II (CGRP-11).3 lAPP is synthesized by islet {1 cells where it Correspondence: K L van Hulst, Department of Endocrinology G02.625, Academic Hospital Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands. is co-localized and co-secreted with insulin.v? Contradictory effects of lAPP on glucose metabolism have been reported. Some investigators found that high doses of lAPP induced insulin resistance in vitro 8 ,9 and in ViVO, and inhibited basal and stimulated insulin secretion.tv '? Others were unable to detect any effect. 18 -26 To study the physiological function of lAPP and its pathophysiological role in diabetes, it is important to have a reliable method for the determination of lAPP levels in plasma. Recently, Initially we also used Sep-Pak C18 cartridge extraction." In time, however, results obtained with this technique turned out to be difficult to reproduce. Therefore we tested different conditions for activating, washing and elution of the cartridges. Tracer recoveries varied from 16 to 89%. As the reproducibility was poor we used another extraction procedure based on acidacetone, followed by a specific and sensitive RIA for lAPP. Using this method, basal plasma lAPP levels and lAPP levels after stimulation with glucagon were determined in pilot studies. This method proved to be more reliable and yielded more reproducible results.
MATERIALS AND METHODS Materials
Human lAPP was purchased from Peninsula (Belmont, CA, USA). 1251-sodium iodide was purchased from Amersham (Buckinghamshire, UK) and Chloramine T from Sigma (St Louis, MO, USA). Gel filtration columns were from Pharmacia (Uppsala, Sweden). The rabbitanti-human-IAPP serum was a gift from Dr A Clark (Oxford, UK). The antiserum had full cross-reactivity with rat lAPP and virtually no cross-reactivity « O' 001%) with CGRP-I. The second antibody-immunoprecipitating reagent, Goat Anti-Rabbit Immunoglobulin, was from Bio-Rad (Richmond, CA, USA).
Methods

Peptide iodination
The chloramine T method was used to iodinate 2· 5 JLg lAPP with 0·5 mCi 1251-sodium iodide.P' Iodinated lAPP was purified by Sephadex G25 gel filtration (PDlO column) followed by Sephadex G75 gel filtration (600 x 9 mm) with 0'9% NaCI-0'25% BSA-1O-4M merthiolate, pH 3·2, eluent. Average incorporation of 125 1 was 71'8±9'7% (range 61-82%, n=6).
Plasma extraction and RIA
One millilitre human plasma samples were extracted with 1· 5 mL acid-acetone (40 mL Ann Clin Biochem 1994: 31 acetone, 1 mL 1 M hydrochloric acid, 5 mL water). For the standard curve, different amounts of synthetic lAPP (0-64 fmol) were added to 'hormone-free' serum in order to obtain a comparable matrix. Hormone-free serum was prepared by adding 8 g charcoal to 100 mL serum followed by an incubation for 16 h at 4°C. Charcoal was removed by centrifugation (3000x g, 30 min, 4°C followed by 50·000 x s. 2 h, 4°C) and filtration (0' 45 JLm). Standard samples were also extracted with acid-acetone. After the precipitate was removed by centrifugation (3000 x g, 25 min, room temperature) the supernatant was lyophilized. The residues were reconstituted in 250 JLL assay buffer (0'1 M phosphate buffer pH 7· 4 containing O'5% BSA). Two hundred microlitre extract was incubated with 40 JLL antiserum (final dilution 1:18000) for 90 h at 4°C. Fifty microlitre iodinated lAPP (± 5000 c.p.m.) was added followed by an incubation for 48 h at 4°C. Separation of free and antibody-bound peptide was performed by second antibody-immunoprecipitation.
Glucagon stimulation test
Stimulation of islet{3 cellsin humans was performed by injecting 1 mg glucagon intravenously. Ethylenediaminetetra-acetic acid (EDTA)-blood was collected before and 6 min after administration. Plasma lAPP levels were determined in duplicate as described in this paper and 200 JLL plasma was used for C-peptide measurement.
RIAs for C-peptide and insulin C-peptide was measured using the NOVO RIA kit for human C-peptide (Novo Industri, Copenhagen, Denmark) after polyethylenglycol treatment of the plasma. For the insulin RIA, World Health Organization standards coded 66-304 were used. 1251-insulin was obtained from Amersham (Buckinghamshire, UK) and the polyclonal antiserum Caris 46 was raised in a rabbit."
Statistics
The relationship between lAPPlinsulin and lAPPIC-peptide levels was tested using Pearson's correlation coefficient (r) and Spearman's rank correlation coefficient (R,) .
RESULTS
Assay characteristics
The human-lAPP-antiserum (hIAPP) was tested for cross-reaction with rat lAPP and with different fragments of human lAPP. The results are shown in Fig. 1 . No displacement was observed using the lAPP fragment 14-24, some displacement was seen using lAPP fragments 14-29 and 25-37 amide. Sephadex G75 gel filtration (600x 9 mm) with 1 M acetic acid eluent of an acid-acetone extracted plasma sample (35 mL) resulted in two peaks of IAPPimmunoreactivity (Fig. 2) . The major peak coincided with both synthetic lAPP and 12~1_IAPP. The second peak was observed in close proximity VI' This peak probably represents (an) lAPP fragment(s). Both components of the immunogram caused tracer displacement parallel to the standard curve, indicating their immunological similarity. The addition of synthetic human lAPP (4 to 64 fmol) to 1 mL plasma resulted in a recovery of 82·3±5·8l1Jo (range 73-93'9l1Jo, n=16). No concentration dependent difference was found.
The extracted-and the non-extracted standard curves showed parallel displacement in the RIA. lAPP in serially diluted plasma samples showed parallel displacement to both standard curves (Fig. 3) . The lower detection limit of the RIA (B o -2SD) was 2·3 ± 0'1 fmol/sample (n = 5). Intra-assay variations determined in plasma samples with mean lAPP concentrations of 4· 3, 17'3 and 32pM were 16'3l1Jo (n= 10), 9'2l1Jo (n = 10) and 6· 2l1Jo (n = 10), respectively. Interassay variations determined for mean lAPP concentrations of 5· 3, 16· 2 and 28 pM were 35·9l1Jo (n=14), 19·9l1Jo (n=15) and 15'4l1Jo (n = 15), respectively. The assays were performed by three different operators.
Applications
Using this method we determined both basal plasma lAPP levels and lAPP levels after stimulation with glucagon. Non-stimulated lAPP levels ranged from 2'4 to 12 pM (mean, 6' 0 ± 4· 0 pM, n = 10) in healthy control subjects (mean BMI 22·6 ± 3' 5 kg/rn-). Correlation coefficients between lAPP/insulin and lAPP/Cpeptide levels were 0·93 (P<O'OOOOI) and 0'92 (P<O'OOOOI), respectively. R, were 0'73 (P<O'OI) and 0·70 (P<0'02), respectively.
Basal lAPP levels were not detectable (< 2· 2 pM) in type 1 diabetic patients (mean BMI 23'3±3'5kg/m 2, n=5) and no change was observed after glucagon administration (Fig. 4) . Variable basal and glucagon-stimulated lAPP levels were found in type 2 diabetic patients (mean BMI 26'9±5'Okg/m 2, n=12). Basal levels ranged from not detectable « 2· 2 pM) to 
DISCUSSION
In this report we describe an improved method for the determination of lAPP levels in plasma.
Using this method we measured both basal and glucagon-stimulated lAPP levels. Although other investigators used Sep-Pak Cl8 cartridge extraction, we find that acid-acetone extraction clearly has some advantages. It is easier to perform, less time consuming and yields more reproducible results. The Sep-Pak extraction method has also been abandoned by Breier et al. 36 because of the critical timing of the loading and elution of the sample. The immunochromatogram of an acid-acetone extracted plasma sample showed two peaks. The major peak coincided with the native lAPP molecule. The second (smaller) peak could arise from (an) lAPP fragment(s). In immunograms of plasma samples of two other subjects, the second peak was much smaller than in the example shown in Fig. 2 , The identity of this peak cannot yet be established with certainty. The human-lAPP-antiserum shows little cross reactivity with the peptides tested. From Fig. 1 could be concluded that the polyclonal antiserum mainly contains antibody populations which recognize the C-terminal region of IAPP probably between the amino acids 24 and 37. It may be, however, that the polyclonal antiserum combines more than one antibody at more than one epitope to give high avidity cyclic complexes with intact lAPP and therefore this cannot be represented by small peptides. Alternatively, the dominant antibody(s) in the polyclonal serum may recognize a conformational epitope not represented in the peptides. Thus, our data do not allow a firm conclusion with respect to the identity of (an) lAPP fragment(s) detected in addition to the intact lAPP molecule. Experiments are in progress to characterize antibodies with improved specificity. A strong positive correlation between IAPPlinsulin and IAPP/Cpeptide levels was found in healthy control subjects, which is consistent with co-localization and co-secretion of lAPP and insulin.v? -0,68 (P<0'02) and -0'61 (P<0'05), respectively ( Fig. 5 ). Plasma lAPP levels were also determined in transgenic mice overexpressing the human lAPP gene (Hoppener et al., unpublished observations). lAPP was measured in 50 to 100 J.lL plasma. In fasted control mice lAPP levels were 57 ± 14 pM (n = 6). Plasma lAPP levels up to 1500 pM were measured in transgenic mice. 
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Relationship between age and increase of plasma islet amyloid polypeptide (lAPP) levels
(r = -0·64, P =0,0245 and R, = -0'68, P<0'05) as well as age and increase of plasma C-peptide levels (r = -0'55, P = 0·0602 and R, = -0'61, P < 0,05) in type 2 diabetic patients (n = 12) after glucagon administration, not detectable «2'2pM) to 38·9pM (Fig. 4) . The increase in lAPP during glucagon administration (~IAPP) varied from 0 to 24' 4 pM. The correlation coefficient betweeñ IAPP and~C-peptide levels was 0·74 (P=0'0057) and s, was 0·71 (P<0·02).
Correlation coefficients between basal lAPP (except for non-detectable values) and C-peptide levels, between stimulated lAPP and C-peptide levels, as well as the overall correlation coefficient between lAPP and C-peptide levels were excellent (,=0'89, ,=0'83 and ,=0'85, P<O'OOOOI, respectively). With increasing age both~IAPP and~C-peptide levels decreased. Correlation coefficients between agel~IAPP and agel~C peptide levels were -0'64 (P=0'0245) and -O' 55 (P= O' 0602), respectively. R, were FIGURE 4. Plasma islet amyloid polypeptide (lAPP) levels before and 6 min after glucagon administration in type 1 (n = 5) and type 2 (n = 12) diabetes mellitus (DM) patients.
Both basal lAPP levels and lAPP levels determined after administration of glucagon were not detectable in type 1 diabetic patients, which is consistent with the destruction of islet (3 cells by the immune system. Variable basal and glucagon-stimulated lAPP levels were found in type 2 diabetic patients. The increase in both lAPP levels (~IAPP) and C-peptide levels (~C-peptide) after glucagon administration decreased with increasing age of the type 2 diabetic patients, probably due to increased amyloid formation. Increased amyloid formation accompanies increased (3 cell destruction in type 2 diabetic monkeys" and man." Once the majority of (3 cells is destroyed plasma lAPP levels are no longer detectable and type 2 diabetic patients need insulin for further treatment (just like type 1 diabetic patients).
We conclude that the presented method for the determination of lAPP in plasma is reliable, reproducible and easy to perform. The ability to measure plasma lAPP levels will help in elucidating the physiological function of lAPP as well as its pathophysiological role in type 2 diabetes mellitus.
